Skip to main content
Premium Trial:

Request an Annual Quote

Appistry, LifeMap Partner on NGS Data Analysis

NEW YORK (GenomeWeb News) – Cloud computing company Appistry today announced a partnership and reseller agreement to integrate LifeMap Sciences' databases into the outputs of genomics pipelines running on Appistry's Ayrris computing environment.

Under the terms of the deal, St. Louis-based Appistry will market next-generation sequencing analysis outputs and reports that include LifeMap's GeneCards and MalaCards data to clinicians and researchers as part of a revenue-sharing arrangement based on the sales of such reports.

LifeMap is a subsidiary of BioTime and holds the exclusive worldwide license to market GeneCards and MalaCards from Yeda Research and Development, the commercial arm of the Weizmann Institute of Science.

Ayrris supports the rapid assembly of data-intensive analytics running on a customer's tools at scale without requiring specialized expertise in high-performance computing or a complex software development effort, Appistry said.

LifeMap's GeneCards database provides concise genomic information on all known and predicted human genes. MalaCards contains information on a wide array of human diseases and the roles genes play in disease processes.

"To realize the promise of personalized medicine, organizations need to scale their bioinformatics pipelines to handle thousands of patient cases, while also providing information physicians can act on," Appistry CEO Kevin Haar said in a statement. "Our partnership with LifeMap enables medical researchers to extend their analytic processes to deliver a better understanding of the biological pathways and disease states associated with genetic samples."

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.